



**HAL**  
open science

## Observational Study of a French and Belgian Multicenter Cohort of 23 Patients Diagnosed in Adulthood With Mevalonate Kinase Deficiency

Cécile Durel, Achille Aouba, Boris Bienvenu, Samuel Deshayes, Brigitte Coppéré, Bruno Gombert, Cécile Acquaviva-Bourdain, Eric Hachulla, Frédéric Lecomte, Isabelle Touitou, et al.

### ► To cite this version:

Cécile Durel, Achille Aouba, Boris Bienvenu, Samuel Deshayes, Brigitte Coppéré, et al.. Observational Study of a French and Belgian Multicenter Cohort of 23 Patients Diagnosed in Adulthood With Mevalonate Kinase Deficiency. *Medicine*, 2016, 95 (11), pp.e3027. 10.1097/MD.0000000000003027. hal-01847009

HAL Id: hal-01847009

<https://hal.umontpellier.fr/hal-01847009>

Submitted on 3 Mar 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

OPEN

# Observational Study of a French and Belgian Multicenter Cohort of 23 Patients Diagnosed in Adulthood With Mevalonate Kinase Deficiency

*Cécile-Audrey Durel, MD, Achille Aouba, MD, PhD, Boris Bienvenu, MD, PhD, Samuel Deshayes, MD, Brigitte Coppéré, MD, Bruno Gombert, MD, Cécile Acquaviva-Bourdain, PhD, Eric Hachulla, MD, PhD, Frédéric Lecomte, MD, Isabelle Touitou, PhD, Jacques Ninet, MD, PhD, Jean-Baptiste Philit, MD, Laurent Messer, MD, Marc Brouillard, MD, Marie-Hélène Girard-Madoux, MD, Michel Moutschen, MD, PhD, Nadia Raison-Peyron, MD, Pascal Hutin, MD, Pierre Duffau, MD, Pierre Trolliet, MD, Pierre-Yves Hatron, MD, Philippe Heudier, MD, Ramiro Cevallos, MD, Thierry Lequerré, MD, PhD, Valentine Brousse, MD, Vincent Lesire, MD, Sylvain Audia, MD, Delphine Maucort-Boulch, MD, PhD, Laurence Cuisset, PhD, and Arnaud Hot, MD, PhD*

**Abstract:** The aim of this study was to describe the clinical and biological features of Mevalonate kinase deficiency (MKD) in patients diagnosed in adulthood.

This is a French and Belgian observational retrospective study from 2000 to 2014. To constitute the cohort, we cross-check the genetic and biochemical databases. The clinical, enzymatic, and genetic data were gathered from medical records.

Twenty-three patients were analyzed. The mean age at diagnosis was 40 years, with a mean age at onset of symptoms of 3 years. All symptomatic patients had fever. Febrile attacks were mostly associated with arthralgia (90.9%); lymphadenopathy, abdominal pain, and skin lesions (86.4%); pharyngitis (63.6%); cough (59.1%); diarrhea, and hepatosplenomegaly (50.0%). Seven patients had psychiatric symptoms (31.8%). One patient developed recurrent seizures. Three patients experienced renal involvement (13.6%). Two patients had angiomyolipoma (9.1%). All but one tested patients had elevated serum immunoglobulin (Ig) D level. Twenty-one patients had genetic diagnosis; most of them were compound heterozygote (76.2%). p.Val377Ile was

the most prevalent mutation. Structural articular damages and systemic AA amyloidosis were the 2 most serious complications. More than 65% of patients displayed decrease in severity and frequency of attacks with increasing age, but only 35% achieved remission.

MKD diagnosed in adulthood shared clinical and genetic features with classical pediatric disease. An elevated IgD concentration is a good marker for MKD in adults. Despite a decrease of severity and frequency of attacks with age, only one-third of patients achieved spontaneous remission.

(*Medicine* 95(11):e3027)

**Abbreviations:** CRP = C-reactive protein, ENT = ear-nose-throat, HIDS = Hyperimmunoglobulinemia D and periodic fever syndrome, Ig = immunoglobulin, IL = Interleukin, MA = mevalonic aciduria, MK = mevalonate kinase, MKD = Mevalonate kinase deficiency.

Editor: Xu-jie Zhou.

Received: September 25, 2015; revised: January 6, 2016; accepted: February 13, 2016.

From the Internal Medicine Department, Edouard Herriot Hospital, Lyon (C-AD, BC, JN, M-HG-M, AH); Internal Medicine Department, Côte de Nacre Hospital, Caen (AA, BB, SD); Medicine and Rheumatology Department, Saint-Louis Hospital, La Rochelle (BG); Inborn Errors of Metabolism Laboratory, Civil Hospital of Lyon, Bron (CA-B); Internal Medicine Department, Claude Huriez Hospital, Lille (EH, P-YH); Polyvalent Medicine Department, Cornouaille Hospital Center, Quimper (FL, PH); Autoinflammatory Diseases Medical Unit, Arnaud Villeuneuve Hospital, Montpellier (IT); Nephrology Department, Metropole Savoie Hospital Center, Chambéry (J-BP); Rheumatology Department, Louis Pasteur Hospital, Colmar (LM); Hematology Department, Arras Hospital Center, Arras, France (MB); Internal Medicine Department, Sart Tilman, Liège, Belgique (MM); Dermatology and Allergy Department, Saint-Eloi Hospital, Montpellier (NR-P); Internal Medicine Department, Saint-André Hospital, Bordeaux (PD); Nephrology Department, Lyon Sud Hospital Center, Pierre-Bénite (PT); Hematology Department, Princesse Grace Hospital Center, Monaco (PH); Internal Medicine Department, Saint-Vincent Hospital Center, Strasbourg (RC); Rheumatology Department, Charles Nicole Hospital, Rouen (TL); Department of Pediatrics, Necker-Enfants Malades Hospital, Paris (VB); Diabetology and Internal Medicine Department, Blois Hospital Center, Blois (VL); Internal Medicine Department, Bocage Central, Dijon (SA); Service de Biostatistique, Hospices civils de Lyon, Université de Lyon 1, Villeurbanne; CNRS, UMR5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, Villeurbanne (DM-B); and Department of Biochemical Genetics, Hospital and Institut Cochin, Paris (LC), France.

Correspondence: Cécile-Audrey Durel, Internal Medicine Department, Edouard Herriot Hospital, 5, place d'Arsonval, 69437 Lyon Cedex 03, France (e-mail: cecile-au@orange.fr, cecile-audrey.durel@chu-lyon.fr).

C-AD and AH have equally contributed to manuscript redaction. All authors took care of the patient and approved the final version of the manuscript. Data were obtained in a manner that could not be directly or indirectly traced back to the patient, so we did not need institutional review board approval based on your national regulations.

Key messages:

- Despite a low mortality rate, the quality of life is altered in adults MKD patients.
- A strong elevated IgD concentration is a good marker for MKD in adults.
- Amyloidosis AA is a rare complication of the long-term course of MKD.

The authors report no conflicts of interest.

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.

This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ISSN: 0025-7974

DOI: 10.1097/MD.0000000000003027

Downloaded from http://journals.lww.com/md-journal by BMD/MS/PH/KAV/DEUM/1010N4+HL/IEZ/26H4/KM/D/0W/CX/1AMV/0P/0H/0D/03/00/0F/7F/SF/HQ/0V/0A/0V/0D/0R/0C/1VEH/SI/0E/0n/03/02/02/01

## INTRODUCTION

Mevalonate kinase deficiency (MKD) is a rare autoinflammatory autosomal recessive periodic fever disorder.<sup>1,2</sup> Hyperimmunoglobulinemia D and periodic fever syndrome (HIDS) and mevalonic aciduria (MA) are both part of the MKD spectrum.<sup>3,4</sup> They result from mutations in the gene encoding mevalonate kinase (MK). This is a key enzyme in cholesterol and non-sterol isoprenoids biosynthesis, which are important compounds in a lot of vital cellular functions. A deficient MK activity leads to shortage of isoprenoids downstream compounds and systemic inflammation through interleukin (IL)-1 $\beta$ -mediation.<sup>5</sup> HIDS and MA are the 2 extreme phenotypes of a continuous spectrum with a mild and severe form, respectively, correlated with the residual MK activity.<sup>6–9</sup> In fact, there must be apparently healthy people to stillbirth.<sup>10</sup> The patients suffered from lifelong febrile attacks that last 3 to 7 days and recur every 4 to 6 weeks with varying associated combination symptoms, such as painful lymphadenopathy, abdominal pain, arthralgia or arthritis, diarrhea and vomiting, skin lesions, headache, cold chills, aphtous ulcers, and hepatosplenomegaly.<sup>11</sup> MA patients had also dysmorphic features, growth retardation, and neurological involvement.

HIDS is the historical name of the pathology and owes its name to the increase of immunoglobulin (Ig) D serum level reported in the first description.<sup>7</sup> Nevertheless, elevated IgD remains an inconsistent finding.<sup>12,13</sup>

Despite a mean diagnostic delay >10 years, first HIDS attacks usually occur in early childhood.<sup>12,14</sup> Exceptional worldwide cases of adult-onset MKD without previous feverish history have been reported but poorly described.<sup>14</sup> We conduct this study to assess the clinical and biological conditions of a multicenter cohort of patients diagnosed with MKD in adulthood. We describe the spectrum of clinical and biological phenotype, and genotype at diagnosis. The long-term complications of the spontaneous course of the disease are noted.

## METHOD

Patients were identified on genetic analysis, or enzymatically proven with a family history of MKD or typical clinical features, in France and Belgian. This was a retrospective study from January 2000 (after the availability of the genetic assay) to December 2014.<sup>3</sup> To constitute an exhaustive cohort, we cross-checked the database of the 2 French competent genetic laboratories in Paris and Montpellier (Drs Cuisset and Touitou) and those of the French specialized biochemical laboratory in Lyon (Dr Acquaviva-Bourdain). The genomic DNA was extracted from primary skin fibroblasts, white blood cells (ie, lymphocytes and leukocytes), or lymphoblasts from MKD patients.

The inclusion criteria were: age upon 16 years at diagnosis; presence of 2 pathological mutations in the MK gene; or low lymphocyte and/or fibroblast MK activity, and/or increased MA in patients with genetically MKD family history and/or typical recurrent febrile attacks (without individual molecular diagnosis). The patients with insufficient collected data were excluded. The data were recorded from the completed questionnaire sent with the enzymatic analysis request, and from the contact with all referring physicians (e-mail and/or phone). The authorizations from physicians and patients were requested. We collected demographic data (gender, age at diagnosis, age at onset of disease, family history, vital status), clinical features (length and recurrence of febrile crises, evolution of crises with increasing age, triggering factors, organ involvement),

**TABLE 1.** Demographic Data

Age at time of diagnosis in years, median/mean (range)	37/40 (16–79)
Age at onset of symptoms in years, median/mean (range)	3/9 (0.2–77)
Age repartition at onset of symptoms, n (%)	
≤6 months	6 (27.3)
6 months–5 years	7 (31.8)
5–10 years	5 (22.7)
>10 years	4 (18.2)
Sex (male/female) (n)	9/14
Familial cases, n (%)	10 (43.5)
Death, n (%)	5 (21.7)

biological evaluation (inflammatory markers, serum Ig concentrations, MK activity, MA, genetic features), histological results if available, and tried treatments after diagnosis. The alternative diagnoses evoked before MKD diagnosis was recorded. The remission was defined as the absence of both clinical symptoms and inflammatory biological syndrome.

## RESULTS

### Demographic Features

Twenty-seven patients were screened. Four patients were excluded: diagnosis before 16 years in 1 patient, and insufficient data in 3 patients. Twenty-three patients (14 women and 9 men) were analyzed, including 1 asymptomatic patient. Some patients have been previously described in case reports or series.<sup>12,14,15</sup>

The demographic data were shown in Table 1. The mean follow-up after diagnosis was 7 years (range 1–13). The mean age at diagnosis was 40 years (range 16–79), with a mean age at onset of symptoms of 9 years (range 0.2–77). A patient had a late onset of manifestations at age of 77 years with a diagnosis made 2 years later. The diagnosis was delayed with a median of 30.6 years after onset of symptoms. Ten patients (43.5%) had familial histories of MKD. Thirteen patients (59.1%) had first clinical features before 5 years, and all but 4 before 10 years (81.8%). At time of diagnosis, 9 patients (40.9%) had a mean of 1 to 2 attacks monthly, and 11 (50%) had ≤1 monthly. Triggering factors were identified in 16 patients (72.7%), which were infection (n = 12), vaccination (n = 9), and condition associated with estrogen level variation as pregnancy in 3 patients and menstrual period in one patient.

Most of the time, febrile attacks were triggered by viral ear-nose-throat infections.

Fourteen patients (60.7%) had an alternative diagnosis before diagnosis of MKD: 9 juvenile idiopathic arthritis, 3 rheumatoid purpura, and 2 acute articular rheumatism.

### Clinical Features

Table 2 showed the main clinical features. Considering the symptomatic patients, febrile attacks were noticed in all patients. The median duration of febrile attacks ranged from 3 to 7 days, never under 2 days or upon 10 days. The articular symptoms affected 21 patients (95.5%), being most of time arthralgia without synovitis (90.9%). One patient developed severe destructive arthritis mimicking rheumatoid arthritis. A tumoral syndrome occurred in 21 patients (95.5%). Nineteen

**TABLE 2.** Clinical Symptoms During Attacks

Symptoms	All Patients (n = 23) (%)	% of Symptomatic Patients (n = 22)
Fever	22 (95.7)	100
Articular symptoms	21 (91.3)	95.5
Arthralgia	20 (87.0)	90.9
Arthritis	11 (47.8)	50.0
Tumoral syndrome	21 (91.3)	95.5
Lymphadenopathy	19 (82.6)	86.4
Hepatomegaly and/or splenomegaly	11 (47.8)	50.0
Gastrointestinal symptoms	20 (87.0)	90.9
Abdominal pain	19 (82.6)	86.4
Diarrhea	11 (47.8)	50.0
Vomiting	7 (30.4)	31.8
Skin lesions	19 (82.6)	86.4
Pharyngitis	14 (60.9)	63.6
Cough	13 (56.5)	59.1
Headache	8 (34.8)	36.4
Aphthous ulcers	7 (30.4)	31.8
Psychiatric symptoms	7 (30.4)	31.8
Ocular symptoms	5 (21.7)	22.7
Conjunctivitis	3 (13.0)	13.6
Uveitis	2 (8.7)	9.1
Optic neuritis	1 (4.3)	4.5
Renal manifestations	3 (13.0)	13.6

patients had lymphadenopathies (82.6%), among whom 16 had cervical localization (84.2%). Hepatomegaly and/or splenomegaly affected 50% of patients. Twenty patients (90.9%) presented with digestive manifestations that were abdominal pain, diarrhea, or vomiting. One patient suffered from cholestasis and recurrent hyperammonemia episodes without other enzymatic deficiencies. The skin lesions were found in 19 patients (86.4%) that were mainly maculopapular rash. Nevertheless, urticarial lesions, and purpura were also reported. One woman experienced chronic cutaneous purpura persisting between attacks. Fourteen patients (63.6%) had pharyngitis, 13 patients (59.1%) experienced cough, and 6 patients (27.3%) suffered from otitis. Headache, aphthous ulcers, and ocular symptoms affected approximately one-third of patients. Three patients (13.0%) had conjunctivitis, 2 patients (9.1%) uveitis, and 1 patient (4.5%) optic neuritis. One patient had recurrent seizures related to MKD that began during adolescence. Psychiatric features, especially depression, were notified

in 7 patients (31.8%). One patient was described as a schizoid personality. We identified 3 patients (13.6%) with renal involvement: segmental and focal glomerulosclerosis, systemic AA amyloidosis, and extracapillar glomerulonephritis. Two patients (9.1%) had renal angiomyolipoma. No macrophage activation syndrome was observed.

**Laboratory Results**

All patients had high elevated C-reactive protein (CRP) during attacks (median 24.1 mg/dL). All patients had microbiological analyses to exclude infectious diseases before considering inflammatory syndrome to be linked to MKD. Between febrile attacks, most of them had normalization of the inflammation markers, but 4 patients had low persistent biological inflammation (CRP ≤1 mg/dL). The biological results are shown in Table 3. An elevated IgD concentration was noted in 20 of the 21 tested patients (median 812 mg/L; range 330–3750); 1 patient had normal IgD concentration. The IgD dosage was high during febrile episode but also between febrile attacks. We used the highest known concentration of IgD to calculate the median and mean values of IgD values in our series. The IgA concentration was elevated to a median level of 7.6 g/L (range 3.8–16.9). The median IgG concentration was in normal range, and the median IgM level was decreased. The median MK activity was decreased to 0.1 μkat/kg protein (range 0–0.45). The median MA was elevated to 5.1 mmol/mol creatinine (range 1.7–28.2).

The MKD diagnosis was genetically confirmed in 21 patients (Table 4). Five patients were homozygous, and 16 were compound heterozygous. p.Val377Ile was the most prevalent mutation with a frequency of 40.5% of all MKD alleles, and was found in 14 of the 21 tested patients (66.7%). The 2 most common mutations (p.Val377Ile and p.Ile268Thr) accounted for 50% of mutations.

Nine patients experienced biopsies (lymphadenopathy, skin, bone marrow) that showed nonspecific neutrophilic inflammatory infiltrates.

**Treatments**

Various treatments were tried to treat and prevent attacks (Table 5). Steroids were prescribed in 19 patients with partial to good response. Nonsteroidal anti-inflammatory therapies were used in 16 patients with an inconstant success. Colchicine (14 patients) and statins (7 patients) were associated with limited or no response. Besides, statins were often bad-tolerated. Interleukin (IL)-1 receptor antagonists were used, with success, in 9 patients. Anti-tumor necrosis factor (TNF)α drugs (infliximab, adalimumab, etanercept) were used in 5 patients with partial response. Apart from those drugs, other molecules were

**TABLE 3.** Laboratory Results

Variable	Results		Available Data, n
	Mean	Median	
Mevalonic aciduria (mmol/mol creatinine) (N <2)	9.1	5.1	13
Mevalonate kinase activity (%) (N = 2.5–7.8)	0.2	0.1	17
Serum Immunoglobulin D level (mg/L) (N = 7.7–132.1)	1145.2	812.0	21
Serum Immunoglobulin A level, g/L (N = 0.8–2.7)	8.3	7.6	13

N: normal value.

**TABLE 4.** Mevalonate Kinase Mutations and Allele Frequencies

Mutation or Deletion	Allele Frequency* (%)	At Least One of This Allele in Patient (n = 21) (%)
p.Val377Ile	40.5	66.7
p.Ile268Thr	9.5	19.0
p.Ala148Thr	9.5	9.5
p.Ala147Thr	4.8	9.5
p.Val321Ala	4.8	9.5
p.Gly212del	4.8	9.5
p.Val310Leu	2.4	4.8
p.Leu230Pro	2.4	4.8
p.Gly336Ser	2.4	4.8
p.Asn205Asp	2.4	4.8
p.Thr237Ser	2.4	4.8
p.Gln218*	2.4	4.8
p.Gln390Pro	2.4	4.8
p.Gly376Ser	2.4	4.8
p.Leu51Phe	2.4	4.8
p.Val247fs	2.4	4.8
p.Thr159Cys*9	2.4	4.8

\* 42 Alleles analyzed.

administered with low or no success, and sometimes not well-tolerated: intravenous immunoglobulins, methotrexate, salazopyrine, hydroxychloroquine, leflunomide, azathioprine, thalidomide, mycophenolate mofetil, cyclosporine, rituximab, abatacept, tocilizumab, lenalidomide.

### Follow-up

More than 65% of patients displayed a significant decrease in severity and frequency of attacks with increasing age, and in the absence of any immunomodulatory drug. Indeed, 12 patients among the 18 questioned patients attested a decrease in the number and the severity of the febrile attacks in adulthood. No data were available for 4 patients because of lost of follow-up. Only 7 patients (35%) achieved remission at the last follow-up visit; 5 of them received IL-1 receptor antagonist.

One woman developed AA amyloidosis that had revealed MKD, with renal and digestive localizations. She first developed proteinuria, then end-stage chronic kidney disease that required dialysis 7 years after MKD diagnosis. One patient had serious destructive arthritis altering quality of life.

Five patients (21.7%) died at a mean age of 56 years; 2 patients had septic shocks (one after digestive occlusion due to amyloid colic stenosis), 2 had solid neoplasms (respectively liver and bladder tumor), and 1 suicide.

### DISCUSSION

This multicenter study reveals that the clinical and genetic spectrum of MKD diagnosed in adulthood does not furiously differ from classical pediatric phenotype. This observational study is, to our knowledge, the only series focusing on adulthood diagnosed MKD. Besides, it is the first to describe the natural history of the disease. The diagnosis delay could be linked to physician misunderstanding.

We confirm that MKD is a multisystemic disorder that could be associated with renal angiomyolipoma, erosive arthritis, crescentic glomerulonephritis, and neuropsychological disorders.<sup>12,14</sup> Moreover, recurrent febrile attacks could lead to a severe complication, that is, AA amyloidosis as in 1 patient in our series. HIDS typical clinical features consist of high-grade fever episodes exceeding 40°C last 3 to 7 days and recurring every 4 to 6 weeks, sometimes triggered by vaccination, infection, trauma, or stress.<sup>16</sup> A triggering factor is noted in 16 patients in our cohort (72.7%). Explanation should be a defective apoptosis of peripheral-blood lymphocytes leading to severe inflammatory response regarding on minor triggering factors.<sup>17</sup> Pregnancy is suspected to trigger attacks in 3 patients in our series, but no physiopathological explanation is known. Reduced triggering events with increasing age may explain the lowest frequency and severity of attacks in adults.

Even if most patients have usually their first febrile attacks within the first year of life, the median age of diagnosis was 10 years with a median diagnosis delay of 9.9 years in the largest published series.<sup>12</sup> In our cohort, >50% of patients are 5 years' old or younger at onset of symptoms with a median age at onset of symptoms of 3 years, but a mean age of 9 years. The early childhood onset of febrile attacks is a key point of diagnosis; the criterion of onset before the age of 5 years is indeed a clinical feature that should evoke MKD.<sup>18</sup> The latest age at onset of symptoms that we report could be explained by a memory bias. Indeed, adult patients self-report their own symptoms that could lead to imprecision. In pediatric studies, the histories of febrile attacks are reported by parents with more precision. However, 3 patients clearly described the beginning of febrile attacks during adolescence. In addition, this series confirms a significant diagnosis delay linked to medical misunderstanding of a rare disease. Moreover, frequent alternative diagnoses are retained before the good diagnosis. The median diagnosis delay in our

**TABLE 5.** Treatments

Medications	Remission, n (%)	Partial response, n (%)	No response, n (%)	Side-effects, n (%)
Prednisone (n = 19)	7 (36.8)	9 (47.4)	3 (15.8)	0 (0)
Non steroidal anti-inflammatory drug (n = 16)	1 (6.3)	11 (68.8)	4 (25.0)	0 (0)
Colchicine (n = 14)	0 (0)	4 (28.6)	8 (57.1)	2 (14.3)
Anti-IL1r (n = 9)	4 (44.4)	5 (55.6)	0 (0)	1 (11.1)
Statin (n = 7)	0 (0)	3 (42.9)	4 (57.1)	3 (42.9)
Anti-TNF $\alpha$ (n = 5)	0 (0)	4 (80.0)	1 (20.0)	0 (0)

IL = interleukin, TNF = tumor necrosis factor.



**TABLE 6.** Comparison of Symptoms During Attacks Between the 2 Reference Previous Series and Our Cohort\*

Symptoms (%)	Bader-Meunier et al, <sup>15</sup> n = 50	Van der Hilst et al, <sup>11</sup> n = 103	Durel et al, n = 23	P
Fever	100	100	100	1
Arthralgia	67	83.5	90.9	0.02
Lymphadenopathy	72	87.4	86.4	0.06
Abdominal pain	65	85.4	86.4	0.01
Skin lesions	67	68.9	86.4	0.17
Diarrhea	70	71.6	50.0	0.12
Arthritis	43	55.3	50.0	0.35
Hepatosplenomegaly	65 <sup>†</sup>	54.0	50.0	0.37
Headache	17	63.3	36.4	<10 <sup>-3</sup>
Vomiting	45	70.9	31.8	<10 <sup>-3</sup>
Aphthous ulcers	43	48.5	31.8	0.28

\* Method: Comparisons between groups were performed by generalized Fisher exact test. When overall significant, the comparison 2 by 2 was performed.

<sup>†</sup> Splenomegaly only.

series is 28.8 years. All these data support that MKD remains a diagnosis challenge, especially in adults.

As previously reported, arthralgia, lymphadenopathy, and abdominal symptoms are the most common organ involvements during attacks in our patients.<sup>12,14</sup> Table 6 shows MKD clinical features in the 2 largest previous series and in our cohort.<sup>12,14</sup> Fever is constant. Arthralgia, abdominal pain, headache, and vomiting are significantly different between the 3 studies, but did not differ between our adulthood series, and the 2 previous series that included pediatric and adult patients. Compared with pediatric MKD, a latest diagnosis tends to lead to most common arthralgia and skin lesions, whereas diarrhea, vomiting, aphthous ulcers, and hepatosplenomegaly are less often reported (NS). There is a similar proportion of lymphadenopathy, abdominal pain, and arthritis. As already described, renal angiomyolipoma is observed in 2 patients. This large renal tumor leads to nephrectomy in one of our patients. The link between angiomyolipoma and MKD is not well explained, but our data and other cases series suggest that this association is not adventitious.<sup>14</sup> In 1 case, MKD is diagnosed in a patient presenting with rapidly progressive crescentic glomerulonephritis; such manifestation has already been reported in MKD course in children.<sup>14,19,20</sup> So, MKD should be evoked in patients presenting with crescentic glomerulonephritis without obvious diagnoses (lupus nephritis, ANCA-associated vasculitis, or Goodpasture disease) and a history of febrile attacks. Cholestasis observed in 1 patient has been previously reported.<sup>21</sup> Psychiatric manifestations are not uncommon, mainly depressive conditions that could be related either to MKD clinical symptoms or owing to patients' health status.<sup>12</sup> For instance, a new case of suicide occurred in 1 of our patients. Regarding neurological features, recurrent seizures occur in 1 patient. This may underline the continuous spectrum between HIDS and MA; no neurologic features are usually reported in HIDS.<sup>6,18</sup> A chronic vasculitic purpura is described in 1 patient. Significantly, this purpura evolves individually without remission between attacks. We report cough as a frequent symptom during attacks. To our best knowledge, this is the first time that cough is described as a clinical feature of MKD. A feverish cough may mimic pulmonary infection and may delay diagnosis of MKD attacks and the corticosteroid introduction. Nevertheless, previous series suggested a susceptibility to bacterial infection

in MKD.<sup>12,14,22</sup> We report 2 deaths related to septic shock, meaning a link between immunodeficiency and MKD.<sup>12,22,23</sup> However, the use of steroids could also explain a part of the infection susceptibility. Conversely to published data, we do not find hypogammaglobulinemia in our cohort.<sup>14,24</sup>

The elevation of IgD has frequently helped guiding physicians to diagnose MKD in our series. Nevertheless, 1 patient exhibits normal IgD level what is concordant with precedent publications.<sup>3,13,25,26</sup> Even if elevated IgD level is also found in other autoinflammatory diseases, strong elevation of IgD (>3 times the upper limit) is more specific for MKD. Our data illustrate the diagnostic value of the IgD dosage in adults compared with children (normal value in 4.3% in adults vs 22% in children).<sup>12,13,27–29</sup> We observed persistent biological inflammatory syndrome between attacks in 4 patients. Surprisingly, the patient diagnosed with AA amyloidosis is not concerned. All of these patients have persistent febrile attacks despite anti-inflammatory drugs.

There is no obvious relation between phenotype and genotype. As already reported, the p.Val377Ile mutation is the most common mutation reported.<sup>14</sup> All the mutations are registered in an online registry called INFEVERS.<sup>30</sup> The 2 most prevalent mutations in our series are p.Val377Ile and p.Ile268Thr that is concordant with previous pediatric series.<sup>12</sup> Two mutations (p.Leu230Pro and p.Val310Leu) have not been reported in children. Most of the others mutations represent only 1 allele in the cohort making difficult to conclude to any association between genetic status and specific clinical features. Furthermore, genotype-phenotype correlation studies in MKD are contradictory.<sup>9,12,14,18,31</sup> Studies promote the hypothesis that there is no strict relationship between genotype and phenotype severity.<sup>9,14</sup> p.Val377Ile is exclusively associated with the mild HIDS phenotype, whereas other mutations are found in both HIDS and MA, such as p.Ile268Thr.<sup>31</sup> p.Val377Ile homozygous patients are attempted to have a milder severity of MKD or to be asymptomatic.<sup>10</sup> In our series, the asymptomatic patient is p.Val377Ile homozygous, like her symptomatic sister with a mild activity of the disease. Nevertheless, one p.Val377Ile homozygous patient in our cohort exhibits a more serious HIDS phenotype. To explain the differences among the clinical spectrum of MKD, modulating factors should exist to attenuate the level of severity. Additional genetic studies should be

performed to identify such potential modifying factors that could be mutations in introns, noncoding exons, squaring sequences or promoters in MK gene, or in another modifying gene. Some studies support the idea of a better correlation between clinical features and residual MK activity that would impact phenotype severity.<sup>3,9,31,32</sup> MK activity is greatly affected in MA (<0.5% of normal) rather than in HIDS with an activity from 1.8% to 28%. In HIDS, most of the MK mutations affect stability or folding of the encoded mutant protein.<sup>3</sup> In MA, mutations must have a more deleterious effect on MK protein folding and/or may direct effect MK catalytic properties.<sup>31</sup> Besides, the residual activity of MK enzyme can be manipulated by environmental conditions; temperature worsens the folding defect.<sup>31,33</sup> This must be clinically relevant in febrile patients, and could explain why ear-nose-throat (ENT) infection is a triggering factor of MKD attacks.

Considering treatments, most of our patients receive corticosteroids or nonsteroidal anti-inflammatory drugs. IL-1 receptor antagonist is used with success in 9 patients. Two prospective trials and others series confirm the effectiveness of anakinra in MKD.<sup>14,34–37</sup> Further data are requested to draw definitive conclusions. This suggests a crucial role of IL-1 and inflammasome in the pathogenesis of MKD.<sup>34,38</sup> Anakinra could be used daily or during febrile attacks only. Furthermore, a continuous treatment with anakinra decreases serum amyloid A level and could so prevent amyloidosis.<sup>37</sup> Anakinra would have greater effect than anti-TNF $\alpha$  agents.<sup>35</sup> Nevertheless, incomplete responses to anakinra suggest the implication of others cytokines.<sup>39</sup> Advances in pathogenesis, that is, inflammasome activation, provide the basis for the development of new therapies. Successful treatment would prevent long-term severe complications.

Indeed, we report 2 infrequent but severe complications. The first case, already published, is a severe erosive arthritis in a young woman mimicking rheumatoid arthritis.<sup>15</sup> There are serious structural damages with narrowing of metacarpophalangeal joint spaces and carpalis. Anakinra allows inflammatory joint pain resolution after failure of sulfasalazine, leflunomide, and etanercept. The second complication is a new case of systemic AA amyloidosis, revealing MKD. AA amyloidosis is a frequent and severe complication in the autoinflammatory diseases, but less common in HIDS (<3%).<sup>40,41</sup> The usual decrease of MKD attacks with increasing age could explain the lowest risk of AA amyloidosis. Indeed, AA amyloidosis complicates disorders with sustained acute-phase response and persistent elevation of serum amyloid A protein level.<sup>42</sup> Unfortunately, we were not able to report the dosage of serum amyloid A protein in our patients. To our knowledge, 5 previous cases of AA amyloidosis in MKD have been published.<sup>43–46</sup> All cases have histories of febrile attacks since childhood, and are 7 to 29 years' old. We report the sixth case. The patient first develops nephrotic syndrome, then end-stage chronic kidney disease, and is finally dialyzed at 69 years. Histories of recurrent febrile attacks have led to MKD diagnosis at 70 years. She suffers from febrile crises for 60 years before onset of an overt proteinuria. She is compound heterozygous (p.Val377Ile - p.Ile268Thr) sharing the same genetic status with another of the 5 patients.<sup>45</sup> Despite lower frequency of AA amyloidosis in MKD, such a condition could complicate long-term course of the disease.<sup>13,47</sup> Early diagnosis and treatment of MKD are needed to prevent development of the life-threatening systemic AA amyloidosis.

To conclude, this study has some limits related to its retrospective character leading to a potential lack of data, and memory bias. We try to limit bias by contacting each referring physicians; we collect a maximum of written

information to ameliorate exhaustivity. Besides, we exclude from analysis 3 patients because of insufficient data. All but 2 cases are genetically proven and systematically collect from laboratories of interest. This is the first study interesting in adulthood MKD and reporting about the spontaneous course of the disease. MKD diagnosed in adulthood shares clinical and genetic features with classical pediatric disease (see Table 6). Interestingly, we report a good diagnostic value of the serum IgD in adults. In cases of suspicion of autoinflammatory disease in adults, we suggest to dose IgD to help physicians to diagnose MKD. Despite the dramatic symptoms during febrile attacks and alteration of quality of life, prognosis remains good. Despite decrease of the severity and frequency of attacks with increasing age, only one-third of patients achieve remission. Amyloidosis AA is rare but could complicate long-term course of MKD. Physicians must keep in mind the existence of yet undiagnosed MKD in adults because diagnosis and initiation of a successful treatment would prevent febrile attacks and their complications, and improve quality of life.

## ACKNOWLEDGMENTS

We want to acknowledge Pr Grateau who has contributed to the scientific content of this article.

## REFERENCES

- Prieur AM, Griscelli C. Nosologic aspects of systemic forms of very early onset juvenile arthritis. Apropos of 17 cases. *Ann Pédiatrie*. 1983;30:565–569.
- Drenth JP, van der Meer JW. Hereditary periodic fever. *N Engl J Med*. 2001;345:1748–1757.
- Houten SM, Kuis W, Duran M, et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinemia D and periodic fever syndrome. *Nat Genet*. 1999;22:175–177.
- Drenth JP, Cuisset L, Grateau G, et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. *Nat Genet*. 1999;22:178–181.
- Henneman L, Schneiders MS, Turkenburg M, et al. Compromized geranylgeranylation of RhoA and Rac1 in mevalonate kinase deficiency. *J Inher Metab Dis*. 2010;33:625–632.
- Simon A, Kremer HPH, Wevers RA, et al. Mevalonate kinase deficiency: evidence for a phenotypic continuum. *Neurology*. 2004;62:994–997.
- Van der Meer JW, Vossen JM, Radl J, et al. Hyperimmunoglobulinemia D and periodic fever: a new syndrome. *Lancet*. 1984;1:1087–1090.
- Berger R, Smit GP, Schierbeek H, et al. Mevalonic aciduria: an inborn error of cholesterol biosynthesis? *Clin Chim Acta Int J Clin Chem*. 1985;152:219–222.
- Cuisset L, Drenth JP, Simon A, et al. Molecular analysis of MVK mutations and enzymatic activity in hyper-IgD and periodic fever syndrome. *Eur J Hum Genet EJHG*. 2001;9:260–266.
- Houten SM, van Woerden CS, Wijburg FA, et al. Carrier frequency of the V377I (1129G>A) MVK mutation, associated with Hyper-IgD and periodic fever syndrome, in the Netherlands. *Eur J Hum Genet EJHG*. 2003;11:196–200.
- Van der Hilst JCH, Simon A, Drenth JPH. Hereditary periodic fever and reactive amyloidosis. *Clin Exp Med*. 2005;5:87–98.
- Van der Hilst JCH, Bodar EJ, Barron KS, et al. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. *Medicine (Baltimore)*. 2008;87:301–310.

13. Ammouri W, Cuisset L, Rouaghe S, et al. Diagnostic value of serum immunoglobulinaemia D level in patients with a clinical suspicion of hyper IgD syndrome. *Rheumatol Oxf Engl*. 2007;46:1597–1600.
14. Bader-Meunier B, Florkin B, Sibilia J, et al. Mevalonate kinase deficiency: a survey of 50 patients. *Pediatrics*. 2011;128:e152–e159.
15. Lequerré T, Vittecoq O, Pouplin S, et al. Mevalonate kinase deficiency syndrome with structural damage responsive to anakinra. *Rheumatol Oxf Engl*. 2007;46:1860–1862.
16. Drenth JP, Haagsma CJ, van der Meer JW. Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. *Medicine (Baltimore)*. 1994;73:133–144.
17. Bodar EJ, van der Hilst JCH, van Heerde W, et al. Defective apoptosis of peripheral-blood lymphocytes in hyper-IgD and periodic fever syndrome. *Blood*. 2007;109:2416–2418.
18. Van der Burgh R, Ter Haar NM, Boes ML, et al. Mevalonate kinase deficiency, a metabolic autoinflammatory disease. *Clin Immunol Orlando Fla*. 2013;147:197–206.
19. Nevyjel M, Pontillo A, Calligaris L, et al. Diagnostics and therapeutic insights in a severe case of mevalonate kinase deficiency. *Pediatrics*. 2007;119:e523–e527.
20. Cailliez M, Garaix F, Rousset-Rouvière C, et al. Crescentic glomerulonephritis is part of hyperimmunoglobulinemia D syndrome. *Pediatr Nephrol Berl Ger*. 2006;21:1917–1918.
21. Hinson DD, Rogers ZR, Hoffmann GF, et al. Hematological abnormalities and cholestatic liver disease in two patients with mevalonate kinase deficiency. *Am J Med Genet*. 1998;78:408–412.
22. D'Osualdo A, Picco P, Caroli F, et al. MVK mutations and associated clinical features in Italian patients affected with autoinflammatory disorders and recurrent fever. *Eur J Hum Genet EJHG*. 2005;13:314–320.
23. Raupp P, Varady E, Duran M, et al. Novel genotype of mevalonic aciduria with fatalities in premature siblings. *Arch Dis Child Fetal Neonatal Ed*. 2004;89:F90–F91.
24. Sornsakrin M, Wenner K, Ganschow R. B cell cytopenia in two brothers with hyper-IgD and periodic fever syndrome. *Eur J Pediatr*. 2009;168:825–831.
25. Saulsbury FT. Hyperimmunoglobulinemia D and periodic fever syndrome (HIDS) in a child with normal serum IgD, but increased serum IgA concentration. *J Pediatr*. 2003;143:127–129.
26. Di Rocco M, Caruso U, Waterham HR, et al. Mevalonate kinase deficiency in a child with periodic fever and without hyperimmunoglobulinaemia D. *J Inheri Metab Dis*. 2001;24:411–412.
27. Livneh A, Drenth JP, Klasen IS, et al. Familial Mediterranean fever and hyperimmunoglobulinemia D syndrome: two diseases with distinct clinical, serologic, and genetic features. *J Rheumatol*. 1997;24:1558–1563.
28. Medlej-Hashim M, Petit I, Adib S, et al. Familial Mediterranean Fever: association of elevated IgD plasma levels with specific MEFV mutations. *Eur J Hum Genet EJHG*. 2001;9:849–854.
29. Dodé C, André M, Bienvenu T, et al. French Hereditary Recurrent Inflammatory Disorder Study Group. The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. *Arthritis Rheum*. 2002;46:2181–2188.
30. Milhavel F, Cuisset L, Hoffman HM, et al. The infevers autoinflammatory mutation online registry: update with new genes and functions. *Hum Mutat*. 2008;29:803–808.
31. Mandey SHL, Schneiders MS, Koster J, et al. Mutational spectrum and genotype-phenotype correlations in mevalonate kinase deficiency. *Hum Mutat*. 2006;27:796–802.
32. Fu Z, Wang M, Potter D, et al. The structure of a binary complex between a mammalian mevalonate kinase and ATP: insights into the reaction mechanism and human inherited disease. *J Biol Chem*. 2002;277:18134–18142.
33. Houten SM, Frenkel J, Rijkers GT, et al. Temperature dependence of mutant mevalonate kinase activity as a pathogenic factor in hyper-IgD and periodic fever syndrome. *Hum Mol Genet*. 2002;11:3115–3124.
34. Kostjukovits S, Kalliokoski L, Antila K, et al. Treatment of hyperimmunoglobulinemia D syndrome with biologics in children: review of the literature and Finnish experience. *Eur J Pediatr*. 2015;74:707–714.
35. Ter Haar N, Lachmann H, Özen S, et al. Paediatric Rheumatology International Trials Organisation (PRINTO) and the Eurofever/Eurotraps Projects. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. *Ann Rheum Dis*. 2013;72:678–685.
36. Galeotti C, Meinzer U, Quartier P, et al. Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency. *Rheumatol Oxf Engl*. 2012;51:1855–1859.
37. Bodar EJ, Kuijk LM, Drenth JPH, et al. On-demand anakinra treatment is effective in mevalonate kinase deficiency. *Ann Rheum Dis*. 2011;70:2155–2158.
38. Normand S, Massonnet B, Delwail A, et al. Specific increase in caspase-1 activity and secretion of IL-1 family cytokines: a putative link between mevalonate kinase deficiency and inflammation. *Eur Cytokine Netw*. 2009;20:101–107.
39. Stoffels M, Jongekrijg J, Remijn T, et al. TLR2/TLR4-dependent exaggerated cytokine production in hyperimmunoglobulinemia D and periodic fever syndrome. *Rheumatol Oxf Engl*. 2015;54:363–368.
40. Bilginer Y, Akpolat T, Ozen S. Renal amyloidosis in children. *Pediatr Nephrol Berl Ger*. 2011;26:1215–1227.
41. Henderson C, Goldbach-Mansky R. Monogenic autoinflammatory diseases: new insights into clinical aspects and pathogenesis. *Curr Opin Rheumatol*. 2010;22:567–578.
42. Gillmore JD, Lovat LB, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. *Lancet*. 2001;358:24–29.
43. Yel S, Gunduz Z, Bastug F, et al. Amyloidosis in a child with hyperimmunoglobulinemia D syndrome. *Iran J Kidney Dis*. 2013;7:70–72.
44. Li Cavoli G, Passantino D, Tortorici C, et al. Renal amyloidosis due to hyper-IgD syndrome. *Nefrol Publ Of Soc Esp Nefrol*. 2012;32:865–866.
45. Lachmann HJ, Goodman HJB, Andrews PA, et al. AA amyloidosis complicating hyperimmunoglobulinemia D with periodic fever syndrome: a report of two cases. *Arthritis Rheum*. 2006;54:2010–2014.
46. Obici L, Manno C, Muda AO, et al. First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome. *Arthritis Rheum*. 2004;50:2966–2969.
47. Siewert R, Ferber J, Horstmann RD, et al. Hereditary periodic fever with systemic amyloidosis: is hyper-IgD syndrome really a benign disease? *Am J Kidney Dis Off J Natl Kidney Found*. 2006;48:e41–e45.